Naurex Inc. is a clinical-stage private company developing novel therapies to address unmet needs in psychiatry and neurology based on a new mechanism of action for modulating the NDMA receptor in a safe way. The company has generated a novel class of compounds - Glycine-site Functional Partial Agonists (GFPAs) - that exhibit marked efficacy consistent with that of traditional NMDAR agents, but without their prohibitive side effects. Naurex's drug candidates have significant potential as therapies for multiple CNS disorders, including mood and anxiety disorders, cognitive disorders, neurodevelopmental disorders, and pain. In August 2015, Allergan plc (NYSE: AGN), a leading global pharmaceutical company, acquired Naurex for a $560 million upfront payment as well as potential R&D success-based and sales-threshold milestone payments.